But don't you think, given the GDNF history in the big pharma world, that surely no one would go down that path again? Not to say that if there are issues, like it doesn't work, they will stop the trial(s), but otherwise I sure would like to believe that they would have thought of GDNF before the human trial started. For example, wouldn't a company have already thought of, and addressed, delivery mechanisms (apparently was a big issue in GDNF?), and either else resigned themselves to the product being delivered by brain surgery and therefore on a one-at-a-time basis (and thus, much less profitable than the en masse take-a-pill one sixe fits all approach)? It's wayyyy too early on a saturday morning to try to articulate what I'm trying to say, but I guess the point is, given GDNF, I would hope they would have worked those kinks out before proceeding this far. But then again...